Alterity Therapeutics (NASDAQ:ATHE) Earns Buy Rating from Analysts at Maxim Group

Maxim Group initiated coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research note issued to investors on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $8.00 price target on the stock.

Alterity Therapeutics Price Performance

Shares of NASDAQ ATHE opened at $2.40 on Thursday. Alterity Therapeutics has a twelve month low of $1.00 and a twelve month high of $3.25. The business’s 50 day moving average price is $1.36 and its two-hundred day moving average price is $1.50.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.